SPRY logo

SPRY
ARS Pharmaceuticals Inc

2,458
Mkt Cap
$778.49M
Volume
3.89M
52W High
$18.90
52W Low
$6.66
PE Ratio
-4.51
SPRY Fundamentals
Price
$8.40
Prev Close
$7.84
Open
$7.99
50D MA
$8.61
Beta
1.23
Avg. Volume
1.62M
EPS (Annual)
-$1.74
P/B
6.81
Rev/Employee
$517,042.95
$1,000.28
Loading...
Loading...
News
all
press releases
Q1 Earnings Forecast for SPRY Issued By Northland Securities
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at Northland Securities issued their Q1 2026 EPS estimates for ARS Pharmaceuticals in a research note issued to investors on Thursday...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by Analysts
Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned a consensus recommendation of "Hold" from the five analysts that are presently covering the stock, Marketbeat Ratings...
MarketBeat·13d ago
News Placeholder
ARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated by Analysts at Northland Securities
Northland Securities initiated coverage on shares of ARS Pharmaceuticals in a report on Thursday. They issued an "outperform" rating and a $25.00 price target on the stock...
MarketBeat·13d ago
News Placeholder
Aberdeen Group plc Purchases 459,027 Shares of ARS Pharmaceuticals, Inc. $SPRY
Aberdeen Group plc raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 14.8% during the fourth quarter, according to its most recent disclosure with the Securities and...
MarketBeat·18d ago
News Placeholder
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy?
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy...
MarketBeat·27d ago
News Placeholder
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7% - Time to Sell?
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7% - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
Bamco Inc. NY grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 3,071.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional...
MarketBeat·1mo ago
News Placeholder
ARS Pharmaceuticals Q4 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company's fourth-quarter and full-year 2025 earnings call to outline early commercial progress for neffy, its needle-free epinephrine option for...
MarketBeat·1mo ago
News Placeholder
ARS Pharmaceuticals: Q4 Earnings Insights
read more...
Benzinga·1mo ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -0.96% and +9.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
<
1
2
...
>

Latest SPRY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.